Intelligence · Clinical Development
Pipeline search results
Programs matching “Gilead Sciences” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 56 pipeline programs matching "Gilead Sciences" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Gilead Sciences Ireland UC
Cystic Fibrosis
1 trial -
B/F/TAF
Gilead Sciences Ireland UC
HIV-1/HBV Co-Infection
1 trial -
B/F/TAF (Adult Strength)
Gilead Sciences Ireland UC
HIV-1 Infection
1 trial -
Bictegravir
Gilead Sciences Ireland UC
HIV-1-infection
2 trials -
CB8025-31731-RE
Gilead Sciences Pty Limited
Primary Biliary Cholangitis
1 trial -
COBI
Gilead Sciences Ireland UC
HIV
1 trial -
E/C/F/TDF
Gilead Sciences Ireland UC
Acquired Immunodeficiency Syndrome
1 trial -
GS-5245 tablets 175 mg, GS-5245 tablets 350 mg
Gilead Sciences Pty Limited
COVID-19
1 trial -
GS-US-174-0144
Gilead Sciences Pty Limited
Hepatitis B Infection
1 trial -
GS-US-528-6727
Gilead Sciences Pty Limited
Human Immunodeficiency Virus (HIV-1) infection
1 trial -
GS-US-563-5925
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-US-563-5926
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-US-577-6153
Gilead Sciences Pty Limited
Non-small cell lung cancer
1 trial -
GS-US-592-6173
Gilead Sciences Pty Limited
PD-L1 Positive Metastatic Triple-Negative Breast Cancer
1 trial -
GS-US-592-6238
Gilead Sciences Pty Limited
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting
1 trial -
GS-US-595-6184
Gilead Sciences Pty Limited
Triple Negative Breast Cancer
1 trial -
GS-US-600-6165
Gilead Sciences Pty Limited
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
GS-US-621-6290
Gilead Sciences Pty Limited
HIV-1 infection
1 trial -
GS-US-621-6463
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-US-626-6216
Gilead Sciences Pty Limited
Metastatic Non–Small Cell Lung Cancer
1 trial -
GS-US-682-6769
Gilead Sciences Pty Limited
Recurrent or Persistent Endometrial Cancer
1 trial -
GS-US-695-6509
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-US-695-7156
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
IMMU-132-13
Gilead Sciences Pty Limited
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.